Wells Fargo analyst David Maris believes MediWound could be more attractive to a broader range of potential buyers, including those in the medical countermeasure space, after the FDA cleared the development pathway for NexoBrid for the debridement of skin injuries inflicted by chemical warfare agent sulfur mustard. The FDA also agreed to allow the development of NexoBrid in sulfur mustard wounds to rely on the chemistry, manufacturing and control data from NexoBrid's previous and ongoing development in burns, Maris points out. He views this as good news for MediWound and keeps an Outperform rating on the shares.

MediWound announced that recent clinical data from EscharEx Phase II studies will be presented throughout May 2024 at the largest, most prestigious annual meetings in the field of chronic wound care: the European Wound Management Association, the Wound Healing Society, and the Symposium on Advanced Wound Care. The oral presentations on EscharEx will include: Comparative data of EscharEx vs. SANTYL that demonstrate EscharEx's superiority over the current leading enzymatic debridement agent; New analyses from the ChronEx phase II study, showing high correlation between wound bed preparation and wound healing; These data indicate that EscharEx could substantially improve wound care for patients with debilitating chronic wounds, providing significant benefits over the current standard of care. Additionally, the findings support the design and endpoints of the upcoming Phase III study, which is expected to begin in the second half of 2024. "We are delighted to present the results of additional analyses from EscharEx Phase II studies in chronic hard-to-heal wounds, including the positive comparative data with SANTYL(R), the current dominant standard of care for enzymatic debridement," said Dr. Robert J. Snyder, Chief Medical Officer of MediWound. "With its robust efficacy, favorable safety profile, and multimodal mechanistic effects demonstrated in these Phase II studies, we believe that EscharEx can significantly advance wound care and has the potential to become a major player in the global wound care market."